{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:03:51Z","timestamp":1789974231826,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":262,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatology Research and Practice"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a relapsing, chronic inflammatory skin disease. Rocatinlimab, an investigational anti\u2010OX40 monoclonal antibody, has been evaluated for moderate\u2010to\u2010severe AD. This systematic review and meta\u2010analysis aimed to evaluate the short\u2010term efficacy and trial\u2010reported safety of subcutaneous rocatinlimab in patients with moderate\u2010to\u2010severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov to identify randomised controlled trials (RCTs) comparing rocatinlimab with placebo in patients with moderate\u2010to\u2010severe AD. Only summary\u2010level data from published reports were analysed. Outcomes of interest included treatment efficacy and safety. A random\u2010effects model with Hartung\u2013Knapp\u2013Sidik\u2013Jonkman adjustment was used for the primary pooled analyses. Exploratory subgroup analyses were conducted according to both dose and dosing frequency, with Wald\u2010type confidence intervals used for subgroup\u2010specific pooled estimates involving only two studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1767 patients from 3 RCTs were included. A total of 1305 patients (73.85%) received subcutaneous rocatinlimab. Rocatinlimab was associated with a significantly greater achievement of the pooled estimate for EASI\u201075 at Week 16 (OR 3.58, 95% CI 1.53\u20138.40;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). The pooled estimate for the vIGA\u2010AD score of 0 or 1 at Week 16 was directionally favourable but imprecise and did not reach statistical significance (OR 4.06, 95% CI 0.56\u201329.47;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09) No statistically significant differences were observed in serious adverse events (OR 1.60, 95% CI 0.41\u20136.26;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.28) or treatment discontinuation due to adverse events (OR 1.28, 95% CI 0.14\u201311.60;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.68), although confidence intervals were wide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In adults with moderate\u2010to\u2010severe AD, subcutaneous rocatinlimab demonstrated potential short\u2010term treatment efficacy compared with placebo. However, the available evidence does not establish durable remission, prevention of recurrence, long\u2010term disease modification or a favourable long\u2010term benefit\u2013risk profile. Given the subsequent discontinuation of the rocatinlimab clinical development programme following safety review, these findings should be interpreted cautiously as a synthesis of short\u2010term trial evidence rather than support for future clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/drp\/2160445","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:50Z","timestamp":1789972130000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Subcutaneous Rocatinlimab in Adults With Moderate\u2010to\u2010Severe Atopic Dermatitis: A Systematic Review and Meta\u2010Analysis of Randomised Placebo\u2010Controlled Trials"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3219-2059","authenticated-orcid":false,"given":"Hong Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5550-6373","authenticated-orcid":false,"given":"Leong Seng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9560-8673","authenticated-orcid":false,"given":"Jordan Wei Lun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1220-3643","authenticated-orcid":false,"given":"Ee Syuen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3820-6763","authenticated-orcid":false,"given":"Yan Ye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005"},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1569119"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14763"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2192"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2025.0057"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2026.02.004"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02037-2"},{"key":"e_1_2_12_9_2","volume-title":"Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials","author":"Kyowa Kirin Co Ltd","year":"2026"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01865-3"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_2_12_13_2","volume-title":"Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program","author":"Kyowa Kirin Co Ltd","year":"2026"},{"key":"e_1_2_12_14_2","volume-title":"Rocatinlimab Clinical Program Discontinuation","author":"Kyowa Kirin Co Ltd","year":"2026"},{"key":"e_1_2_12_15_2","volume-title":"Covidence Systematic Review Software","year":"2023"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_12_17_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins J. P. T.","year":"2024"},{"key":"e_1_2_12_18_2","unstructured":"The Cochrane Collaboration Review Manager (RevMan)."},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0091-1"},{"key":"e_1_2_12_21_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann H. J.","year":"2024"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0782-0"}],"container-title":["Dermatology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/drp\/2160445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/drp\/2160445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/drp\/2160445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:55Z","timestamp":1789972135000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/drp\/2160445"}},"subtitle":[],"editor":[{"given":"Anjali","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/drp\/2160445"],"URL":"https:\/\/doi.org\/10.1155\/drp\/2160445","archive":["Portico"],"relation":{},"ISSN":["1687-6105","1687-6113"],"issn-type":[{"value":"1687-6105","type":"print"},{"value":"1687-6113","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2160445"}}